Rentschler will expand production capacity at its Laupheim, Germany facility to support the increasing demand for complex antibodies. A report published by vfa bio and Boston Consulting Group assessing the state of biotech in Germany revealed the country is falling behind in production capacity when compared globally to others.  to other countries. “While companies in the US, South Korea, Ireland, and Switzerland have expanded their production facilities in the last three years, there has been no growth at all in…
Friday, July 2, 2021 Daily Archives
AGC Bio takes the Longmont jump, buying CO plant from Novartis
CDMO AGC Bio has picked up a second site in Colorado, buying a cell and gene therapy facility in Longmont from Novartis. The 622,000 square-foot facility in Longmont – north of Denver, Colorado – will become part of AGC Biologics’ ever-growing manufacturing footprint, and will go hand-in-hand with its cell and gene therapy site in Milan, Italy, added through the €240 million ($284 million) acquisition of Molmed last year. “The Longmont facility fits perfectly into AGC’s long-term growth and expansion…
Lonza invests $21m to expand China facility
Lonza says the expansion of its high potency API facility in Nansha, China will help support growing demand for ADC production. Swiss contract development manufacturing organization (CDMO) Lonza will add three 1,000 L GMP trains, including development laboratories with the capacity to produce small scale batches of highly potent APIs (HPAPIs). The expanded site will also boast six 1,000 L small molecule reactors, four 1,500L vessels, and isolation equipment adding capacity for a smooth transition between early-phase and large-scale commercial…
Cytiva doubles liquid cell culture media capacity with Intermountain bolt-on
The latest acquisition by Cytiva sees it add Intermountain Life Sciences, gaining a buffer and cell culture media manufacturing site in Utah. Terms of the deal have not been disclosed, but Danaher Corporation subsidiary Cytiva has added a 25,000+ square-foot facility in Salt Lake City, Utah. The site can produce 60,000 L/day of Water for Injection (WFI) and formulation lot sizes to 14,000 L, and will significantly expand Cytiva’s bioprocessing offering, said Olivier Loeillot, VP of Cytiva. “This acquisition is…
Bayer CDMO Viralgen opens doors for AAV manufacturing
Viralgen has opened an $83 million AAV production site in San Sebastian, the first gene therapy production facility in Spain. Contract development and manufacturing organization (CDMO) Viralgen said in November 2019 it would be constructing Spain’s first commercial gene therapy production site at the Miramon Technology Park in San Sebastian to add capacity for gene therapy manufacturing services. The president of the Basque Government in Spain, Iñigo Urkullu and Pedro Duque, Minister of Science and Innovation of the Spanish government opened the facility…